Literature DB >> 23179553

Brain magnetic resonance imaging findings in patients with mucopolysaccharidosis VI.

Ana C M Azevedo1, Osvaldo Artigalás, Leonardo Vedolin, Márcia Komlós, Adriana Pires, Roberto Giugliani, Ida Vanessa D Schwartz.   

Abstract

INTRODUCTION: Mucopolysaccharidosis type VI (MPS VI) is a rare lysosomal storage disorder caused by the deficient activity of N-acetylgalactosamine 4-sulfatase. MPS VI is usually considered as not being associated with mental retardation. AIMS/
METHODS: The main objective of the present study was to describe brain magnetic resonance imaging (MRI) findings and their correlation with clinical and biochemical findings in MPS VI patients. The study was conducted at Hospital de Clínicas de Porto Alegre, Brazil with 25 MPS VI patients. All patients were evaluated through clinical evaluation, IQ tests, urinary glycosaminoglycans (GAG) analysis, and brain MRI.
RESULTS: Mean age at evaluation was 10.6 ± 4.52 years. Five of 16 patients presented total IQ below the normal range. Brain MRI was abnormal in the majority of patients (n = 19/21), and the most frequent abnormalities found were the presence of dilated perivascular spaces and white matter lesions. Correlations were found between age and normalized white matter lesion load (NLL) (r = 0.46; p = 0.04) and normalized cerebral volume (NCV) (r = -0.56; p = 0.01), between NLL and height deficit (r = 0.48; p = 0.04), and between NCV and weight deficit (r = -0.58; p = 0.01) and height deficit (r = -0.55; p = 0.01). A correlation between urinary GAG levels and quantitative brain MRI findings was not found, neither between qualitative and quantitative brain MRI findings and IQ scores.
CONCLUSIONS: MPS VI patients may present abnormal IQ scores without correlation with brain abnormalities on the MRI, a finding which was found to be very frequent in MPS VI. Additional studies are required to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179553     DOI: 10.1007/s10545-012-9559-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  21 in total

1.  Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation.

Authors:  M Gisele Matheus; Mauricio Castillo; J Keith Smith; Diane Armao; Diane Towle; Joseph Muenzer
Journal:  Neuroradiology       Date:  2004-06-17       Impact factor: 2.804

Review 2.  Management guidelines for mucopolysaccharidosis VI.

Authors:  Roberto Giugliani; Paul Harmatz; James E Wraith
Journal:  Pediatrics       Date:  2007-08       Impact factor: 7.124

3.  Craniovertebral abnormalities in Type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome).

Authors:  J A Thorne; M Javadpour; D G Hughes; E Wraith; R A Cowie
Journal:  Neurosurgery       Date:  2001-04       Impact factor: 4.654

4.  Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.

Authors:  Paul Harmatz; David Ketteridge; Roberto Giugliani; Natalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; Zi-Fan Yu; Stuart J Swiedler; John J Hopwood
Journal:  Pediatrics       Date:  2005-06       Impact factor: 7.124

5.  Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate clinical phenotype caused by substitution of valine for glycine at position 137 of arylsulfatase B.

Authors:  G Wicker; V Prill; D Brooks; G Gibson; J Hopwood; K von Figura; C Peters
Journal:  J Biol Chem       Date:  1991-11-15       Impact factor: 5.157

6.  Mental retardation in a patient with Maroteaux-Lamy.

Authors:  S Vestermark; T Tønnesen; M S Andersen; F Güttler
Journal:  Clin Genet       Date:  1987-02       Impact factor: 4.438

Review 7.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

8.  Mutational analysis of 105 mucopolysaccharidosis type VI patients.

Authors:  Litsa Karageorgos; Doug A Brooks; Anthony Pollard; Elizabeth L Melville; Leanne K Hein; Peter R Clements; David Ketteridge; Stuart J Swiedler; Michael Beck; Roberto Giugliani; Paul Harmatz; James E Wraith; Nathalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; John J Hopwood
Journal:  Hum Mutat       Date:  2007-09       Impact factor: 4.878

9.  Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence.

Authors:  Gunilla Malm; Allan M Lund; Jan-Eric Månsson; Arvid Heiberg
Journal:  Acta Paediatr       Date:  2008-08-04       Impact factor: 2.299

10.  Brain MRI in mucopolysaccharidosis: effect of aging and correlation with biochemical findings.

Authors:  L Vedolin; I V D Schwartz; M Komlos; A Schuch; A C Azevedo; T Vieira; F K Maeda; A M Marques da Silva; R Giugliani
Journal:  Neurology       Date:  2007-08-28       Impact factor: 9.910

View more
  4 in total

Review 1.  The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy.

Authors:  Anna-Maria Wiesinger; Brian Bigger; Roberto Giugliani; Maurizio Scarpa; Tobias Moser; Christina Lampe; Christoph Kampmann; Florian B Lagler
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

2.  Evaluation of spinal involvement in children with mucopolysaccharidosis VI: the role of MRI.

Authors:  Elif Bulut; Emine Pektas; Hatice S Sivri; Burcak Bilginer; Mumtaz M Umaroglu; Burce Ozgen
Journal:  Br J Radiol       Date:  2018-02-13       Impact factor: 3.039

3.  Long-term cognitive follow-up in children treated for Maroteaux-Lamy syndrome.

Authors:  Berendine J Ebbink; Marion M G Brands; Johanna M P van den Hout; Maarten H Lequin; Robert R J Coebergh van den Braak; Rianne L van de Weitgraven; Iris Plug; Femke K Aarsen; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2015-10-08       Impact factor: 4.982

Review 4.  Non-cardiac Manifestations in Adult Patients With Mucopolysaccharidosis.

Authors:  Karolina M Stepien; Andrew Bentley; Cliff Chen; M Wahab Dhemech; Edward Gee; Peter Orton; Catherine Pringle; Jonathan Rajan; Ankur Saxena; Govind Tol; Chaitanya Gadepalli
Journal:  Front Cardiovasc Med       Date:  2022-03-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.